Deep inside the bone marrow, a covert operation has been running for decades. Acute myeloid leukemia - AML for short - is the double agent that slipped past your body's counterintelligence, forging fake IDs for rogue blood cells and smuggling them into circulation. For years, oncologists have been running two competing extraction teams to take these moles down: one deploys a Trojan-horse liposome loaded with two chemotherapy drugs (codename: CPX-351), and the other sends in a precision assassin that disables the cancer cell's self-destruct override (venetoclax paired with hypomethylating agents). The burning question at headquarters: which team gets the job done?
A massive new retrospective study from Mayo Clinic involving 600 patients just dropped some intel - and the answer is more complicated than anyone's press release would suggest.
The Contenders, Briefly
CPX-351 (brand name: Vyxeos) is a nano-scale liposome that packages cytarabine and daunorubicin at a precise 5:1 molar ratio. Think of it as a tiny delivery drone that preferentially docks with leukemia cells in the bone marrow and releases its payload at the optimal synergistic dose. It earned FDA approval in 2017 specifically for secondary AML - the kind that evolves from prior blood disorders or previous chemotherapy (Lancet et al., JCO 2018).
Venetoclax plus a hypomethylating agent (Ven-HMA) takes a completely different approach. Venetoclax is a BCL-2 inhibitor - it blocks the protein that leukemia cells use to dodge programmed cell death. Pair it with azacitidine or decitabine, and you've got a one-two punch that's become the go-to frontline treatment for older or less-fit AML patients (ASH 2025 Guidelines, Blood Advances).
So we've got a liposomal chemotherapy package versus a targeted apoptosis trigger. Heavyweight bout. Let's see the scorecards.
600 Patients, One Unsatisfying Answer
Fathima and colleagues at Mayo Clinic looked at 112 patients treated with CPX-351 and 488 who received Ven-HMA. Right away, these groups weren't identical - CPX-351 patients were younger (median age 65 vs. 73), more often female, and more likely to have secondary AML. That matters, because comparing them head-to-head is a bit like comparing marathon runners who started at different mile markers.
The headline finding? Complete response rates were comparable between the two regimens, and overall survival was broadly similar - median 10 months for CPX-351 versus 13 months for Ven-HMA. Before Ven-HMA fans start popping champagne, those three extra months largely disappeared after adjusting for age and other variables. For patients with adverse-risk cytogenetics, TP53 mutations, or IDH mutations, outcomes were statistically indistinguishable between the two (Fathima et al., Blood Cancer J. 2026).
Where Things Get Interesting (And Specific)
Here's where the spy thriller gets its twist. Two subgroups broke the tie:
-
Post-MDS AML (leukemia that evolved from myelodysplastic syndromes): Ven-HMA delivered superior survival - median 12 versus 7 months. That's a meaningful gap for a patient population with notoriously tough disease.
-
SF3B1-mutated AML: CPX-351 patients hadn't even reached their median survival at the time of analysis, versus 14 months for Ven-HMA. For a specific mutation, that's a dramatic swing in the opposite direction.
The takeaway isn't that one drug wins. It's that the answer depends on who your patient is and what their leukemia looks like under the molecular microscope.
Why This Actually Matters
I'll be honest - we've all seen the "Treatment A versus Treatment B, results were similar" study before. Your inner skeptic (hi, that's me) might shrug. But this study is useful precisely because the overall result is a tie. It tells clinicians that for most patients, either regimen is a reasonable choice, which shifts the decision to practical factors: fitness level, mutation profile, transplant candidacy, and side effect tolerance.
It also reinforces something the field has been slowly learning: AML isn't one disease. It's a collection of molecularly distinct cancers wearing the same trench coat. Treating them all identically was always a bit optimistic. Real-world studies analyzing outcomes by subtype, like this one from a growing body of comparative data, are what will eventually let oncologists match patients to treatments with something approaching precision.
The Bottom Line
Neither CPX-351 nor Ven-HMA has knocked the other out. For now, treatment selection in older AML patients remains a judgment call shaped by molecular genetics, disease history, and patient fitness. The real breakthrough won't be declaring a single winner - it'll be getting good enough at molecular profiling that we stop asking "which drug is better?" and start asking "which drug is better for this patient?"
Until then, both extraction teams stay on active duty.
References:
-
Fathima S, Rokach L, Ghosoun N, et al. CPX-351 (Liposomal Cytarabine and Daunorubicin) versus venetoclax plus hypomethylating agent therapy in newly diagnosed acute myeloid leukemia: a retrospective comparison involving 600 Mayo Clinic patients. Blood Cancer J. 2026. DOI: 10.1038/s41408-026-01495-x
-
Lancet JE, Uy GL, Cortes JE, et al. CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. J Clin Oncol. 2018;36(26):2684-2692. DOI: 10.1200/JCO.2017.77.6112. PMID: 30024784
-
American Society of Hematology 2025 guidelines for treating newly diagnosed acute myeloid leukemia in older adults. Blood Advances. 2025;10(6):1897. PMID: 41321225
-
Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia. Blood Advances. 2022;6(13):3997. DOI: 10.1182/bloodadvances.2022007265
-
The Role of CPX-351 in the Acute Myeloid Leukemia Treatment Landscape: Mechanism of Action, Efficacy, and Safety. Drugs. 2025. DOI: 10.1007/s40265-025-02194-w
Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.